A novel neutrophil extracellular traps-related lncRNA signature predicts prognosis in patients with early-stage lung adenocarcinoma

References

• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):1–17. doi: 10.1038/nature25183.
   Web of Science ®Google Scholar
• Xu S, Wang Y, Ren F, et al. Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: an analysis of the cancer genome atlas data. Cancer Med. 2020;9(20):7686–7694. doi: 10.1002/cam4.3403.
   PubMed Web of Science ®Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300. doi: 10.21037/tlcr.2016.06.07.
   PubMed Web of Science ®Google Scholar
• Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl.):e1S–e29S. doi: 10.1378/chest.12-2345.
   PubMed Web of Science ®Google Scholar
• Park CK, Cho HJ, Choi YD, et al. A phase II trial of osimertinib in the second-line treatment of non-small cell lung cancer with the EGFR T790M mutation, detected from circulating tumor DNA: LiquidLung-O-Cohort 2. Cancer Res Treat. 2019;51(2):777–787. doi: 10.4143/crt.2018.387.
   PubMed Web of Science ®Google Scholar
• Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4(11):1543–1552. doi: 10.1001/jamaoncol.2018.3676.
   PubMed Web of Science ®Google Scholar
• Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507–519. doi: 10.1038/s41422-020-0337-2.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. Immunology’s foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nat Immunol. 2008;9(7):705–712. doi: 10.1038/ni0708-705.
   PubMed Web of Science ®Google Scholar
• Ballesteros I, Rubio-Ponce A, Genua M, et al. Co-option of neutrophil fates by tissue environments. Cell. 2020;183(5):1282–1297.e18. doi: 10.1016/j.cell.2020.10.003.
   PubMed Web of Science ®Google Scholar
• Rosales C. Neutrophils at the crossroads of innate and adaptive immunity. J Leukoc Biol. 2020;108(1):377–396. doi: 10.1002/JLB.4MIR0220-574RR.
   PubMed Web of Science ®Google Scholar
• Paczoska-Eliasiewicz H, Popek W, Rzasa J, et al. Histochemical demonstration of the presence of serotonin in the hen (Gallus domesticus) reproductive tract. Folia Biol. 1990;38:27–33.
   PubMed Web of Science ®Google Scholar
• Rajarathnam K, Schnoor M, Richardson RM, et al. How do chemokines navigate neutrophils to the target site: dissecting the structural mechanisms and signaling pathways. Cell Signal. 2019;54:69–80. doi: 10.1016/j.cellsig.2018.11.004.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Prause O, Sjöstrand M, et al. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J Immunol. 2003;170(9):4665–4672. doi: 10.4049/jimmunol.170.9.4665.
   PubMed Web of Science ®Google Scholar
• Prince LR, Allen L, Jones EC, et al. The role of interleukin-1beta in direct and toll-like receptor 4-mediated neutrophil activation and survival. Am J Pathol. 2004;165(5):1819–1826. doi: 10.1016/s0002-9440(10)63437-2.
   PubMed Web of Science ®Google Scholar
• Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159–2167. doi: 10.1182/blood-2018-11-844548.
   PubMed Web of Science ®Google Scholar
• Mizuno R, Kawada K, Itatani Y, et al. The role of tumor-associated neutrophils in colorectal cancer. Int J Mol Sci. 2019;20(3):529.
   PubMed Web of Science ®Google Scholar
• Antuamwine BB, Bosnjakovic R, Hofmann-Vega F, et al. N1 versus N2 and PMN-MDSC: a critical appraisal of current concepts on tumor-associated neutrophils and new directions for human oncology. Immunol Rev. 2023;314(1):250–279. doi: 10.1111/imr.13176.
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16(3):183–194. doi: 10.1016/j.ccr.2009.06.017.
   PubMed Web of Science ®Google Scholar
• Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol. 2019;9:1146. doi: 10.3389/fonc.2019.01146.
   PubMed Web of Science ®Google Scholar
• Cedervall J, Hamidi A, Olsson AK. Platelets, NETs and cancer. Thromb Res. 2018;164(Suppl. 1):S148–S152. doi: 10.1016/j.thromres.2018.01.049.
   PubMedGoogle Scholar
• Garley M, Jabłońska E, Dąbrowska D. NETs in cancer. Tumour Biol. 2016;37(11):14355–14361. doi: 10.1007/s13277-016-5328-z.
   PubMedGoogle Scholar
• Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–1535. doi: 10.1126/science.1092385.
   PubMed Web of Science ®Google Scholar
• Tadie JM, Bae HB, Jiang S, et al. HMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor 4. Am J Physiol Lung Cell Mol Physiol. 2013;304(5):L342–L349. doi: 10.1152/ajplung.00151.2012.
   PubMed Web of Science ®Google Scholar
• Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012;109(32):13076–13081. doi: 10.1073/pnas.1200419109.
   PubMed Web of Science ®Google Scholar
• Demers M, Wagner DD. Neutrophil extracellular traps: a new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology. 2013;2(2):e22946. doi: 10.4161/onci.22946.
   PubMed Web of Science ®Google Scholar
• Oklu R, Sheth RA, Wong KHK, et al. Neutrophil extracellular traps are increased in cancer patients but does not associate with venous thrombosis. Cardiovasc Diagn Ther. 2017;7(Suppl. 3):S140–S149. doi: 10.21037/cdt.2017.08.01.
   PubMedGoogle Scholar
• Li Y, Yang Y, Gan T, et al. Extracellular RNAs from lung cancer cells activate epithelial cells and induce neutrophil extracellular traps. Int J Oncol. 2019;55(1):69–80. doi: 10.3892/ijo.2019.4808.
   PubMed Web of Science ®Google Scholar
• Demkow U. Neutrophil extracellular traps (NETs) in cancer invasion, evasion and metastasis. Cancers. 2021;13(17):4495. doi: 10.3390/cancers13174495.
   PubMed Web of Science ®Google Scholar
• Masucci MT, Minopoli M, Del Vecchio S, et al. The emerging role of neutrophil extracellular traps (NETs) in tumor progression and metastasis. Front Immunol. 2020;11:1749. doi: 10.3389/fimmu.2020.01749.
   PubMed Web of Science ®Google Scholar
• Cools-Lartigue J, Spicer J, McDonald B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123(8):3446–3458. doi: 10.1172/JCI67484.
   PubMed Web of Science ®Google Scholar
• Kanamaru R, Ohzawa H, Miyato H, et al. Neutrophil extracellular traps generated by low density neutrophils obtained from peritoneal lavage fluid mediate tumor cell growth and attachment. J Vis Exp. 2018;(138). doi: 10.3791/58201.
   Google Scholar
• Erpenbeck L, Schön MP. Neutrophil extracellular traps: protagonists of cancer progression? Oncogene. 2017;36(18):2483–2490. doi: 10.1038/onc.2016.406.
   PubMed Web of Science ®Google Scholar
• Poto R, Cristinziano L, Modestino L, et al. Neutrophil extracellular traps, angiogenesis and cancer. Biomedicines. 2022;10(2):431. doi: 10.3390/biomedicines10020431.
   PubMed Web of Science ®Google Scholar
• Lerman I, Hammes SR. Neutrophil elastase in the tumor microenvironment. Steroids. 2018;133:96–101. doi: 10.1016/j.steroids.2017.11.006.
   PubMed Web of Science ®Google Scholar
• Wada Y, Yoshida K, Tsutani Y, et al. Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines. Oncol Rep. 2007;17:161–167. doi: 10.3892/or.17.1.161.
   PubMed Web of Science ®Google Scholar
• Teijeira Á, Garasa S, Gato M, et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity. 2020;52(5):856–871.e8. doi: 10.1016/j.immuni.2020.03.001.
   PubMed Web of Science ®Google Scholar
• Kaltenmeier C, Yazdani HO, Morder K, et al. Neutrophil extracellular traps promote T cell exhaustion in the tumor microenvironment. Front Immunol. 2021;12:785222. doi: 10.3389/fimmu.2021.785222.
   PubMed Web of Science ®Google Scholar
• Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost. 2014;40(3):277–283. doi: 10.1055/s-0034-1370765.
   PubMed Web of Science ®Google Scholar
• Yazdani HO, Roy E, Comerci AJ, et al. Neutrophil extracellular traps drive mitochondrial homeostasis in tumors to augment growth. Cancer Res. 2019;79(21):5626–5639. doi: 10.1158/0008-5472.CAN-19-0800.
   PubMed Web of Science ®Google Scholar
• Statello L, Guo CJ, Chen LL, et al. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96–118. doi: 10.1038/s41580-020-00315-9.
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981. doi: 10.1158/0008-5472.CAN-16-2634.
   PubMed Web of Science ®Google Scholar
• Deng H, Zhang J, Shi J, et al. Role of long non-coding RNA in tumor drug resistance. Tumour Biol. 2016;37(9):11623–11631. doi: 10.1007/s13277-016-5125-8.
   PubMed Web of Science ®Google Scholar
• Wu X, Sui Z, Zhang H, et al. Integrated analysis of lncRNA-mediated ceRNA network in lung adenocarcinoma. Front Oncol. 2020;10:554759. doi: 10.3389/fonc.2020.554759.
   PubMed Web of Science ®Google Scholar
• Lu L, Liu LP, Zhao QQ, et al. Identification of a ferroptosis-related LncRNA signature as a novel prognosis model for lung adenocarcinoma. Front Oncol. 2021;11:675545. doi: 10.3389/fonc.2021.675545.
   PubMed Web of Science ®Google Scholar
• Gao H, Wang X, Lin C, et al. Exosomal MALAT1 derived from ox-LDL-treated endothelial cells induce neutrophil extracellular traps to aggravate atherosclerosis. Biol Chem. 2020;401(3):367–376. doi: 10.1515/hsz-2019-0219.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu F, Chen L, et al. Neutrophil extracellular traps (NETs) promote non-small cell lung cancer metastasis by suppressing lncRNA MIR503HG to activate the NF-κB/NLRP3 inflammasome pathway. Front Immunol. 2022;13:867516. doi: 10.3389/fimmu.2022.867516.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo L, Dai Q, et al. A signature for pan-cancer prognosis based on neutrophil extracellular traps. J Immunother Cancer. 2022;10(6):e004210. doi: 10.1136/jitc-2021-004210.
   PubMed Web of Science ®Google Scholar
• Najmeh S, Cools-Lartigue J, Giannias B, et al. Simplified human neutrophil extracellular traps (NETs) isolation and handling. J Vis Exp. 2015;(98):52687. doi: 10.3791/52687.
   Google Scholar
• Jaillon S, Galdiero MR, Del Prete D, et al. Neutrophils in innate and adaptive immunity. Semin Immunopathol. 2013;35(4):377–394. doi: 10.1007/s00281-013-0374-8.
   PubMed Web of Science ®Google Scholar
• Agraz-Cibrian JM, Giraldo DM, Mary FM, et al. Understanding the molecular mechanisms of NETs and their role in antiviral innate immunity. Virus Res. 2017;228:124–133. doi: 10.1016/j.virusres.2016.11.033.
   PubMed Web of Science ®Google Scholar
• Liu D, Wan Y, Qu N, et al. LncRNA-FAM66C was identified as a key regulator for modulating tumor microenvironment and hypoxia-related pathways in glioblastoma. Front Public Health. 2022;10:898270. doi: 10.3389/fpubh.2022.898270.
   PubMed Web of Science ®Google Scholar
• Xiao K, Peng G. Long non-coding RNA FAM66C regulates glioma growth via the miRNA/LATS1 signaling pathway. Biol Chem. 2022;403(7):679–689. doi: 10.1515/hsz-2021-0333.
   PubMed Web of Science ®Google Scholar
• Neal JW, Gainor JF, Shaw AT. Developing biomarker-specific end points in lung cancer clinical trials. Nat Rev Clin Oncol. 2015;12(3):135–146. doi: 10.1038/nrclinonc.2014.222.
   PubMed Web of Science ®Google Scholar
• Duncan MW. Place for biochemical markers in early-stage lung cancer detection? J Clin Oncol. 2009;27(17):2749–2750. doi: 10.1200/JCO.2009.22.4337.
   PubMed Web of Science ®Google Scholar
• Cedervall J, Zhang Y, Olsson AK. Tumor-induced NETosis as a risk factor for metastasis and organ failure. Cancer Res. 2016;76(15):4311–4315. doi: 10.1158/0008-5472.CAN-15-3051.
   PubMed Web of Science ®Google Scholar
• Brostjan C, Oehler R. The role of neutrophil death in chronic inflammation and cancer. Cell Death Discov. 2020;6(1):26. doi: 10.1038/s41420-020-0255-6.
   PubMed Web of Science ®Google Scholar
• Inamura K. Major tumor suppressor and oncogenic non-coding RNAs: clinical relevance in lung cancer. Cells. 2017;6(2):12. doi: 10.3390/cells6020012.
   PubMed Web of Science ®Google Scholar
• Zhu J, Zhu S, Yu Q, et al. LncRNA FAM66C inhibits pancreatic cancer progression by sponging miR-574-3p. Transl Cancer Res. 2020;9(3):1806–1817. doi: 10.21037/tcr.2020.02.24.
   PubMed Web of Science ®Google Scholar
• Xie Y, Gu J, Qin Z, et al. Long non-coding RNA FAM66C is associated with clinical progression and promotes cell proliferation by inhibiting proteasome pathway in prostate cancer. Cell Biochem Funct. 2020;38(8):1006–1016. doi: 10.1002/cbf.3531.
   PubMed Web of Science ®Google Scholar
• Lei GL, Li Z, Li YY, et al. Long noncoding RNA FAM66C promotes tumor progression and glycolysis in intrahepatic cholangiocarcinoma by regulating hsa-miR-23b-3p/KCND2 axis. Environ Toxicol. 2021;36(11):2322–2332. doi: 10.1002/tox.23346.
   PubMed Web of Science ®Google Scholar
• Zhang C, Dang D, Liu C, et al. Identification of tumor mutation burden-related hub genes and the underlying mechanism in melanoma. J Cancer. 2021;12(8):2440–2449. doi: 10.7150/jca.53697.
   PubMed Web of Science ®Google Scholar
• Yang XZ, Ma L, Fang SX, et al. Construction of a competing endogenous RNA network and identification of potential regulatory axes in gastric cancer chemoresistance. Pathol Res Pract. 2022;234:153904. doi: 10.1016/j.prp.2022.153904.
   PubMed Web of Science ®Google Scholar
• Sun Z, Dang Q, Liu Z, et al. LINC01272/miR-876/ITGB2 axis facilitates the metastasis of colorectal cancer via epithelial–mesenchymal transition. J Cancer. 2021;12(13):3909–3919. doi: 10.7150/jca.55666.
   PubMed Web of Science ®Google Scholar
• Leng X, Liu G, Wang S, et al. LINC01272 promotes migration and invasion of gastric cancer cells via EMT. Onco Targets Ther. 2020;13:3401–3410. doi: 10.2147/OTT.S242073.
   PubMedGoogle Scholar
• Fu H, Zhang Z, Li D, et al. LncRNA PELATON, a ferroptosis suppressor and prognostic signature for GBM. Front Oncol. 2022;12:817737. doi: 10.3389/fonc.2022.817737.
   PubMedGoogle Scholar
• Zhang S, Zhou J. Low LINC01272 predicts poor prognosis of non-small cell lung cancer and its biological function in tumor cells by inhibiting miR-1303. Oncol Lett. 2021;22(3):652. doi: 10.3892/ol.2021.12913.
   PubMed Web of Science ®Google Scholar
• Chen WJ, Tang RX, He RQ, et al. Clinical roles of the aberrantly expressed lncRNAs in lung squamous cell carcinoma: a study based on RNA-sequencing and microarray data mining. Oncotarget. 2017;8(37):61282–61304. doi: 10.18632/oncotarget.18058.
   PubMedGoogle Scholar
• Ma J, Zhang M, Yu J. Identification and validation of immune-related long non-coding RNA signature for predicting immunotherapeutic response and prognosis in NSCLC patients treated with immunotherapy. Front Oncol. 2022;12:899925. doi: 10.3389/fonc.2022.899925.
   PubMed Web of Science ®Google Scholar
• Ma X, Liu Y, Tian H, et al. LINC01272 suppressed cell multiplication and induced apoptosis via regulating MiR-7-5p/CRLS1 axis in lung cancer. J Microbiol Biotechnol. 2021;31(7):921–932. doi: 10.4014/jmb.2102.02010.
   PubMed Web of Science ®Google Scholar
• Jin D, Song Y, Chen Y, et al. Identification of a seven-lncRNA immune risk signature and construction of a predictive nomogram for lung adenocarcinoma. Biomed Res Int. 2020;2020:7929132. doi: 10.1155/2020/7929132.
   PubMed Web of Science ®Google Scholar
• Lu Y, Luo X, Wang Q, et al. A novel Necroptosis-Related lncRNA signature predicts the prognosis of lung adenocarcinoma. Front Genet. 2022;13:862741. doi: 10.3389/fgene.2022.862741.
   PubMedGoogle Scholar
• He C, Yin H, Zheng J, et al. Identification of immune-associated lncRNAs as a prognostic marker for lung adenocarcinoma. Transl Cancer Res. 2021;10(2):998–1012. doi: 10.21037/tcr-20-2827.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Q, Shen H, et al. Identification and validation of a three pyroptosis-related lncRNA signature for prognosis prediction in lung adenocarcinoma. Front Genet. 2022;13:838624. doi: 10.3389/fgene.2022.838624.
   PubMed Web of Science ®Google Scholar
• Gong Z, Li Q, Li J, et al. A novel signature based on autophagy-related lncRNA for prognostic prediction and candidate drugs for lung adenocarcinoma. Transl Cancer Res. 2022;11(1):14–28. doi: 10.21037/tcr-21-1554.
   PubMed Web of Science ®Google Scholar
• Fenton SE, Saleiro D, Platanias LC. Type I and II interferons in the anti-tumor immune response. Cancers. 2021;13(5):1037. doi: 10.3390/cancers13051037.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Rosenthal R, Hiley CT, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259–1271.e11. doi: 10.1016/j.cell.2017.10.001.
   PubMed Web of Science ®Google Scholar
• Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–150. doi: 10.1038/s41568-019-0116-x.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype–immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi: 10.1016/j.celrep.2016.12.019.
   PubMed Web of Science ®Google Scholar
• Chen Z, Fan L, Wang H, et al. Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties. Nat Neurosci. 2022;25(1):39–49. doi: 10.1038/s41593-021-00971-w.
   PubMed Web of Science ®Google Scholar